Following much controversy over Catalyst Pharma’s decision to put a $375,000 price tag on a Lambert-Eaton myasthenic syndrome (LEMS) treatment that was originally being provided for free by Jacobus Pharmaceuticals, Jacobus has received the Food and Drug Administration’s (FDA) green light on a potential off-label competitor.
According to a FiercePharma report, Jacobus’ Ruzurgi has been approved to treat LEMS in patients between the ages of 6 and 17 years old. Catalyst’s Firdapse was approved for adults.
Prior to the controversy, Jacobus had been providing amifampridine, which had not cleared by the FDA, to patients for decades free of charge through the agency’s compassionate use program.
To read the full report on FiercePharma, click here.